Neoleukin Therapeutics (NASDAQ:NLTX) Director Bros. Advisors Lp Baker Purchases 371,525 Shares

Share on StockTwits

Neoleukin Therapeutics (NASDAQ:NLTX) Director Bros. Advisors Lp Baker acquired 371,525 shares of the firm’s stock in a transaction on Wednesday, August 7th. The shares were acquired at an average price of $3.00 per share, with a total value of $1,114,575.00.

Neoleukin Therapeutics stock opened at $3.23 on Thursday. Neoleukin Therapeutics has a 52-week low of $2.00 and a 52-week high of $4.23.

About Neoleukin Therapeutics

Neoleukin Therapeutics, Inc, a biopharmaceutical company, develops immunotherapies using protein design technology. The company's lead product candidate is NL-201, a computationally-designed de novo protein therapeutic for the treatment of IL-2/IL-15 cancer immunotherapy. It also engages in research activities for the treatment of autoimmunity and allergy.

Featured Story: Trading signals using Bollinger bands

Receive News & Ratings for Neoleukin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neoleukin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Nanometrics  Lifted to Hold at BidaskClub
Nanometrics Lifted to Hold at BidaskClub
Nasdaq  Downgraded by BidaskClub
Nasdaq Downgraded by BidaskClub
NetScout Systems  Raised to “Hold” at BidaskClub
NetScout Systems Raised to “Hold” at BidaskClub
Intellia Therapeutics  Raised to Hold at BidaskClub
Intellia Therapeutics Raised to Hold at BidaskClub
Northern Trust  Lifted to “Hold” at BidaskClub
Northern Trust Lifted to “Hold” at BidaskClub
Liberty Latin America  Upgraded at BidaskClub
Liberty Latin America Upgraded at BidaskClub


© 2006-2019 Ticker Report